DalsnaFinance

Charles River Laboratories $CRL

Health Care · Life Sciences Tools & Services · NYSE/NASDAQ

S&P 500 Russell 1000 Massachusetts
Create a scorecard
$314.37
+14.35 (+4.78%)
As of Oct 20, 2026, 12:59 PM EDT
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Jul 20, 2026, the first target we tracked for CRL.

Key facts

52-week range (closes)
$149.93 – $310.77 Lowest close May 18, 2026, highest Oct 5, 2026; 251 daily closes to Oct 13, 2026 from Dalsna Finance's price archive
Fiscal year ends
December Fiscal 2025 ended Dec 27, 2025, from SEC filings
In the S&P 500 since
May 14, 2021, replacing FLIR Systems (FLIR) · Teledyne Technologies acquired FLIR Systems. · All S&P 500 changes
Analyst coverage
4 open price targets from 4 firms: CLSA, Evercore ISI, Jefferies, JPMorgan Approved targets tracked here; see the analyst section below

Charles River Laboratories (CRL) is trading up at $314.37 (+4.78%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.

Analyst price targets on CRL

Current price targets from 4 firms average $292, median $305, ranging from $219 to $340 — the average is 7% below the current $314. Each is tracked to its date and scored the same way a member's call is.

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Charles River Laboratories revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)
$4.13B$1.99B−$144.3MFY2016 revenue: $1.68BFY2016 net income: $154.8M · Net margin 9.2%'16FY2017 revenue: $1.86BFY2017 net income: $123.4M · Net margin 6.6%'17FY2018 revenue: $2.27BFY2018 net income: $226.4M · Net margin 10.0%'18FY2019 revenue: $2.62BFY2019 net income: $252.0M · Net margin 9.6%'19FY2020 revenue: $2.92BFY2020 net income: $364.3M · Net margin 12.5%'20FY2021 revenue: $3.54BFY2021 net income: $391.0M · Net margin 11.0%'21FY2022 revenue: $3.98BFY2022 net income: $486.2M · Net margin 12.2%'22FY2023 revenue: $4.13BFY2023 net income: $474.6M · Net margin 11.5%'23FY2024 revenue: $4.05BFY2024 net income: $22.2M · Net margin 0.5%'24FY2025 revenue: $4.02BFY2025 net income: −$144.3M · Net margin −3.6%'250%10%20%30%FY2016 net margin: 9.2%FY2017 net margin: 6.6%FY2018 net margin: 10.0%FY2019 net margin: 9.6%FY2020 net margin: 12.5%FY2021 net margin: 11.0%FY2022 net margin: 12.2%FY2023 net margin: 11.5%FY2024 net margin: 0.5%FY2025 net margin: −3.6% (off the scale, which stops at −1.0%)
Charles River Laboratories annual financial statements
FY2016Dec 2016FY2017Dec 2017FY2018Dec 2018FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$1.68B$1.86B$2.27B$2.62B$2.92B$3.54B$3.98B$4.13B$4.05B$4.02B
Growth (year over year)+23.3%+10.5%+22.0%+15.7%+11.5%+21.1%+12.3%+3.9%−1.9%−0.9%
Gross profit$1.40B$1.57B————————
Gross margin83.5%84.4%————————
Operating income$237.6M$288.3M$331.4M$351.2M$432.7M$589.9M$651.0M$617.3M$227.3M$25.2M
Operating margin14.1%15.5%14.6%13.4%14.8%16.7%16.4%14.9%5.6%0.6%
Net income$154.8M$123.4M$226.4M$252.0M$364.3M$391.0M$486.2M$474.6M$22.2M−$144.3M
Net margin9.2%6.6%10.0%9.6%12.5%11.0%12.2%11.5%0.5%−3.6%
EPS (diluted)$3.23$2.54$4.62$5.07$7.20$7.60$9.48$9.22$0.20−$2.91
Balance sheet
Cash and equivalents$117.6M$163.8M$195.4M$238.0M$228.4M$241.2M$233.9M$276.8M$194.6M$213.8M
Total assets$2.71B$2.93B$3.86B$4.69B$5.49B$7.02B$7.60B$8.20B$7.53B$7.14B
Total liabilities$1.86B$1.87B$2.52B$3.03B$3.35B$4.43B$4.58B$4.54B$4.02B$3.92B
Long-term debt$1.19B$1.09B$1.63B$1.85B$1.93B$2.66B$2.71B$2.65B$2.24B$2.14B
Shareholders' equity$836.8M$1.05B$1.32B$1.63B$2.11B$2.53B$2.98B$3.60B$3.46B$3.16B
Cash flow
Operating cash flow$316.9M$318.1M$441.1M$480.9M$546.6M$760.8M$619.6M$683.9M$734.6M$737.6M
Capital expenditure$55.3M$82.4M$140.1M$140.5M$166.6M$228.8M$324.7M$318.5M$233.0M$219.2M
Free cash flow$261.6M$235.6M$301.1M$340.4M$380.0M$532.0M$294.9M$365.4M$501.6M$518.5M
Share buybacks$12.3M$106.9M$13.8M$18.1M$24.0M$40.7M$38.7M$24.2M$119.2M$360.7M

From Charles River Laboratories's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

Charles River Laboratories vs the Health Care sector and the S&P 500

Charles River Laboratories's latest reported figures next to the median of the other 59 S&P 500 Health Care companies and of the other 502 S&P 500 companies; each median is taken over the companies with a comparable figure (counts in the footnote). A median is the middle value, not an average, so one very large company does not move it.

Charles River Laboratories compared with the median Health Care company and the median S&P 500 company
MeasureCharles River LaboratoriesHealth Care (59 other S&P 500 companies)S&P 500 (502 other companies)
Revenue growth, latest fiscal year−0.9%+7.2%+7.0%
Net margin, latest fiscal year−3.6%13.1%13.0%
Share price change, 1 year+62.9%+19.8%+5.6%

Charles River Laboratories: fiscal year ended December 2025, from its 10-K and 10-Q filings with the SEC. Medians computed October 20, 2026 from each company's latest annual filing (fiscal years ending between July 2025 and September 2026) and our price archive. Prices for every company, Charles River Laboratories included, are the last regular-session prices of October 19, 2026; the 1-year change compares that price with each company's last close on or before October 20, 2025. Net margin and price change are our calculations from reported figures. Each median counts only the companies with a comparable figure (sector / S&P 500): revenue growth 59/496, net margin 59/496, 1-year price change 59/490; the reasons below can overlap. 12 are left out of the price figure because our archive holds no comparable close for them. The S&P 500 price figure is the middle company's change, not the index's return.

About Charles River Laboratories

Charles River Laboratories International, Incorporated is an American life sciences company and contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides goods and services that support the development of drugs, vaccines, and other therapeutics. Its operations span at least 20 countries, offering research models, drug discovery and safety assessment, and manufacturing and testing services to pharmaceutical, biotechnology, government, and other clients.

Source: Wikipedia — Charles River Laboratories

Headquarters
Wilmington, Massachusetts From SEC filings, Oct 2026

Recent News (20)

More Health Care stocks

Browse all companies →